Pub Date : 2026-02-01Epub Date: 2026-01-16DOI: 10.1016/j.jaccao.2025.12.002
Isabela Landsteiner MD , Stephen J. Foulkes PhD , Joseph Campain MD , Carly E. Camphausen BSc , Daniel A. Zlotoff MD, PhD , Gregory D. Lewis MD , Mark J. Haykowsky PhD
{"title":"Reduced Exercise Capacity in Breast Cancer Compared to HFpEF","authors":"Isabela Landsteiner MD , Stephen J. Foulkes PhD , Joseph Campain MD , Carly E. Camphausen BSc , Daniel A. Zlotoff MD, PhD , Gregory D. Lewis MD , Mark J. Haykowsky PhD","doi":"10.1016/j.jaccao.2025.12.002","DOIUrl":"10.1016/j.jaccao.2025.12.002","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"8 1","pages":"Pages 80-82"},"PeriodicalIF":12.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145991262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2026-02-17DOI: 10.1016/j.jaccao.2025.11.002
Aron Onerup MD, PhD , Qi Liu MSc , Shizue Izumi PhD , José Miguel Martínez-Martínez PhD , Stephanie B. Dixon MD, MPH , Eric J. Chow MD, MPH , Melissa M. Hudson MD , Claire Snyder PhD , Paul C. Nathan MD, MSc , Gregory T. Armstrong MD, MSCE , Kirsten K. Ness PhD , Yutaka Yasui PhD
{"title":"Potential of Exercise for Prevention of Cardiovascular Disease in Survivors of Childhood Hodgkin Lymphoma","authors":"Aron Onerup MD, PhD , Qi Liu MSc , Shizue Izumi PhD , José Miguel Martínez-Martínez PhD , Stephanie B. Dixon MD, MPH , Eric J. Chow MD, MPH , Melissa M. Hudson MD , Claire Snyder PhD , Paul C. Nathan MD, MSc , Gregory T. Armstrong MD, MSCE , Kirsten K. Ness PhD , Yutaka Yasui PhD","doi":"10.1016/j.jaccao.2025.11.002","DOIUrl":"10.1016/j.jaccao.2025.11.002","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"8 1","pages":"Pages 87-89"},"PeriodicalIF":12.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146221573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2026-02-17DOI: 10.1016/j.jaccao.2025.11.003
Jean Henri Maselli-Schoueri MD, PhD , Samuel David Saibil MD, PhD , Victor Gabriel da Silva Negrini MD , Ary Serpa Neto MD, MSc, PhD , Marcus Butler MD
{"title":"Beyond the Hazard Ratio","authors":"Jean Henri Maselli-Schoueri MD, PhD , Samuel David Saibil MD, PhD , Victor Gabriel da Silva Negrini MD , Ary Serpa Neto MD, MSc, PhD , Marcus Butler MD","doi":"10.1016/j.jaccao.2025.11.003","DOIUrl":"10.1016/j.jaccao.2025.11.003","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"8 1","pages":"Pages 90-92"},"PeriodicalIF":12.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146221161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Incretin mimetics (glucagon-like peptide-1 receptor agonists and dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonists) are paradigm changing for managing obesity, diabetes, and cardiovascular risk. These phenotypes are also associated with elevated risk for numerous cancers. Limited research suggests that incretin mimetics may be associated with lower risk for developing several cancers. However, more translational and randomized clinical data are needed for confirmation. Patients with cancer were excluded from trials of incretin mimetics. Therefore, their effects on adipose tissue, muscle, cardiovascular risk factors, and outcomes in this population are unknown. Notwithstanding contraindications with a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, translational data also promote the hypothesis that incretin mimetics could slow the growth of other cancers. Further clinical data are needed to determine which patients undergoing cancer treatment might experience benefit or harm from the anthropometric and calorie reduction effects of incretin mimetics or display cardiometabolic benefit despite the competing risk for cancer death.
{"title":"Incretin Mimetics in Cancer and Cardiovascular Disease","authors":"Darryl Leong MBBS, MPH, MBiostat, PhD , Selena Gong BHSc , Naveed Sattar MB, ChB, PhD , Vivek Narayan MD, MSCE , Natalie M. Reizine MD , Hertzel Gerstein MD, MSc , Jordan Vellky PhD","doi":"10.1016/j.jaccao.2025.12.003","DOIUrl":"10.1016/j.jaccao.2025.12.003","url":null,"abstract":"<div><div>Incretin mimetics (glucagon-like peptide-1 receptor agonists and dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonists) are paradigm changing for managing obesity, diabetes, and cardiovascular risk. These phenotypes are also associated with elevated risk for numerous cancers. Limited research suggests that incretin mimetics may be associated with lower risk for developing several cancers. However, more translational and randomized clinical data are needed for confirmation. Patients with cancer were excluded from trials of incretin mimetics. Therefore, their effects on adipose tissue, muscle, cardiovascular risk factors, and outcomes in this population are unknown. Notwithstanding contraindications with a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, translational data also promote the hypothesis that incretin mimetics could slow the growth of other cancers. Further clinical data are needed to determine which patients undergoing cancer treatment might experience benefit or harm from the anthropometric and calorie reduction effects of incretin mimetics or display cardiometabolic benefit despite the competing risk for cancer death.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"8 1","pages":"Pages 1-16"},"PeriodicalIF":12.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146221189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2026-02-17DOI: 10.1016/j.jaccao.2025.12.001
Javier E. Sierra-Pagan MD, PhD , Michael G. Levin MD
{"title":"Cardiovascular Risk Prediction in Breast Cancer Survivors","authors":"Javier E. Sierra-Pagan MD, PhD , Michael G. Levin MD","doi":"10.1016/j.jaccao.2025.12.001","DOIUrl":"10.1016/j.jaccao.2025.12.001","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"8 1","pages":"Pages 77-79"},"PeriodicalIF":12.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146221115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2026-02-17DOI: 10.1016/j.jaccao.2025.12.008
Olayiwola Bolaji MD , Samantha Brown MS , Brian C. Shaffer MD , Glenn Heller PhD , Marie-Claude Beaulieu MD , James E. Ip MD , Carol L. Chen MD , Sergio Giralt MD , Ioanna Kosmidou MD , Heather J. Landau MD , Usmani Saad MD , Michael Scordo MD , Gunjan Shah MD , Roni Shouval MD , Anthony F. Yu MD , Jennifer E. Liu MD
Background
Atrial fibrillation (AF) is a common and clinically significant complication in cancer patients, but data on its incidence and impact among multiple myeloma (MM) patients undergoing autologous stem cell transplantation (ASCT) remain limited.
Objectives
The aim of this study was to characterize the incidence, predictors, and prognostic implications of AF following ASCT in MM patients.
Methods
A total of 801 MM patients who underwent ASCT between 2016 and 2022 were retrospectively analyzed. Pretransplantation evaluation included electrocardiography and echocardiography within 180 days of conditioning. Patients with AF at baseline were excluded. Post-transplantation AF was defined as electrocardiography-confirmed AF occurring after stem cell infusion.
Results
Over a median follow-up period of 36.2 months, 70 patients (8.7%) developed post-transplantation AF. The cumulative incidence was 5.5% at 90 days and 9.0% at 3 years, with a median onset of 13 days. Independent predictors included age >65 years (HR: 1.88; 95% CI: 1.16-3.07), prior paroxysmal AF (HR: 6.19; 95% CI: 3.63-10.5), and obesity (HR: 2.00; 95% CI: 1.10-3.63). Left atrial volume index >34 mL/m2 (HR: 1.67; 95% CI: 0.99-2.80) and corrected QT interval >480 ms (HR: 1.69; 95% CI: 0.91-3.12) were associated with AF but not statistically significant after adjustment. Among patients without prior AF, corrected QT interval >480 ms remained a significant predictor. In multivariable analysis, post-transplantation AF conferred a 5-fold higher risk for all-cause mortality and a 4.5-fold higher risk for nonrelapse mortality.
Conclusions
AF is a frequent and high-risk complication among MM patients undergoing ASCT. Routinely available clinical factors enable risk stratification, underscoring the importance of cardiovascular evaluation and vigilant post-transplantation monitoring in this vulnerable population.
{"title":"Atrial Fibrillation Following Autologous Stem Cell Transplantation in Multiple Myeloma","authors":"Olayiwola Bolaji MD , Samantha Brown MS , Brian C. Shaffer MD , Glenn Heller PhD , Marie-Claude Beaulieu MD , James E. Ip MD , Carol L. Chen MD , Sergio Giralt MD , Ioanna Kosmidou MD , Heather J. Landau MD , Usmani Saad MD , Michael Scordo MD , Gunjan Shah MD , Roni Shouval MD , Anthony F. Yu MD , Jennifer E. Liu MD","doi":"10.1016/j.jaccao.2025.12.008","DOIUrl":"10.1016/j.jaccao.2025.12.008","url":null,"abstract":"<div><h3>Background</h3><div>Atrial fibrillation (AF) is a common and clinically significant complication in cancer patients, but data on its incidence and impact among multiple myeloma (MM) patients undergoing autologous stem cell transplantation (ASCT) remain limited.</div></div><div><h3>Objectives</h3><div>The aim of this study was to characterize the incidence, predictors, and prognostic implications of AF following ASCT in MM patients.</div></div><div><h3>Methods</h3><div>A total of 801 MM patients who underwent ASCT between 2016 and 2022 were retrospectively analyzed. Pretransplantation evaluation included electrocardiography and echocardiography within 180 days of conditioning. Patients with AF at baseline were excluded. Post-transplantation AF was defined as electrocardiography-confirmed AF occurring after stem cell infusion.</div></div><div><h3>Results</h3><div>Over a median follow-up period of 36.2 months, 70 patients (8.7%) developed post-transplantation AF. The cumulative incidence was 5.5% at 90 days and 9.0% at 3 years, with a median onset of 13 days. Independent predictors included age >65 years (HR: 1.88; 95% CI: 1.16-3.07), prior paroxysmal AF (HR: 6.19; 95% CI: 3.63-10.5), and obesity (HR: 2.00; 95% CI: 1.10-3.63). Left atrial volume index >34 mL/m<sup>2</sup> (HR: 1.67; 95% CI: 0.99-2.80) and corrected QT interval >480 ms (HR: 1.69; 95% CI: 0.91-3.12) were associated with AF but not statistically significant after adjustment. Among patients without prior AF, corrected QT interval >480 ms remained a significant predictor. In multivariable analysis, post-transplantation AF conferred a 5-fold higher risk for all-cause mortality and a 4.5-fold higher risk for nonrelapse mortality.</div></div><div><h3>Conclusions</h3><div>AF is a frequent and high-risk complication among MM patients undergoing ASCT. Routinely available clinical factors enable risk stratification, underscoring the importance of cardiovascular evaluation and vigilant post-transplantation monitoring in this vulnerable population.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"8 1","pages":"Pages 17-27"},"PeriodicalIF":12.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146221114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2026-02-17DOI: 10.1016/j.jaccao.2025.12.005
Artur Schneider DO , Elizabeth A. Mauricio MD , Melissa A. Lyle MD
{"title":"Calling All Carriers","authors":"Artur Schneider DO , Elizabeth A. Mauricio MD , Melissa A. Lyle MD","doi":"10.1016/j.jaccao.2025.12.005","DOIUrl":"10.1016/j.jaccao.2025.12.005","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"8 1","pages":"Pages 45-47"},"PeriodicalIF":12.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146221152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号